Evaluation of IPSS-M and exploratory prognostic model for MDS at the time of HMA failure.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ajh.27043 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Clinical Characteristics and Prognosis of Myelodysplastic Syndromes Patients with Gene Mutation].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
August 2024
Department of Hematology, The Second Affiliated Hospital (Tangdu Hospital) of Air Force Medical University, Xi'an 710038, Shaanxi Province, China.
Objective: To investigate the clinical characteristics and survival analysis of myelodysplastic syndromes (MDS) with gene mutation.
Methods: Clinical data of 177 newly diagnosed MDS patients admitted to the Department of Hematology, the Second Affiliated Hospital of Air Force Military Medical University from October 1, 2015 to October 31, 2022 were retrospectively analyzed. Gene mutation detection was performed by second-generation sequencing technology, and clinical characteristics and prognosis of patients with gene mutation were analyzed.
Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes.
J Intern Med
July 2024
Center for Hematology and Regenerative Medicine (HERM), Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
Background: The Molecular International Prognostic Scoring System (IPSS-M) is the new gold standard for diagnostic outcome prediction in patients with myelodysplastic syndromes (MDS). This study was designed to assess the additive prognostic impact of dynamic transfusion parameters during early follow-up.
Methods: We retrieved complete transfusion data from 677 adult Swedish MDS patients included in the IPSS-M cohort.
Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study.
J Clin Oncol
October 2023
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Article Synopsis
- Allogeneic hematopoietic cell transplantation (HCT) significantly enhances overall survival in patients with myelodysplastic syndrome (MDS), especially in those with specific genetic mutations.
- *In a study of 309 patients aged 50-75 with high-risk MDS, those with gene mutations showed poorer survival without HCT but improved outcomes when they did undergo transplantation.
- *Patients classified as very high risk according to the molecular IPSS who lacked mutations also benefited strongly from having a donor available during treatment.
Mutational Profile Enables the Identification of a High-Risk Subgroup in Myelodysplastic Syndromes with Isolated Trisomy 8.
Cancers (Basel)
July 2023
IBSAL, IBMCC, CSIC, Cancer Research Center, University of Salamanca, 37007 Salamanca, Spain.
Trisomy 8 (+8) is the most frequent trisomy in myelodysplastic syndromes (MDS) and is associated with clinical heterogeneity and intermediate cytogenetic risk when found in isolation. The presence of gene mutations in this group of patients and the prognostic significance has not been extensively analyzed. Targeted deep sequencing was performed in a cohort of 79 MDS patients showing isolated +8.
View Article and Find Full Text PDFPerformance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure.
Am J Hematol
October 2023
Department of Leukemia, MD Anderson Cancer Center, Houston, Texas, USA.
Evaluation of IPSS-M and exploratory prognostic model for MDS at the time of HMA failure.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!